Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac Discovery, an independent member of the Almac Group, has selected Beactica for drug discovery platform.
Subscribe to our email newsletter
Under the agreement, Beactica will use its drug discovery platform, Sprint, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.
Beactica CEO Per Kallblad said that they have selected Beactica’s platform to identify high-quality medicinal chemistry starting points for a number of their prioritised programs.
Financial terms of the agreement were not disclosed.